| Literature DB >> 32130499 |
Diego Kaski1,2.
Abstract
The diagnosis and management of vertigo remains a challenge for clinicians, including general neurology. In recent years there have been advances in the understanding of established vestibular syndromes, and the development of treatments for existing vestibular diagnoses. In this 'update' I will review how our understanding of previously "unexplained" dizziness in the elderly is changing, explore novel insights into the pathophysiology of vestibular migraine, and its relationship to the newly coined term 'persistent postural perceptual dizziness', and finally discuss how a simple bedside oculomotor assessment may help identify vestibular presentations of stroke.Entities:
Keywords: Dizziness; Persistent postural perceptual dizziness (PPPD); Small vessel disease cerebral; Vestibular; Vestibular migraine
Year: 2020 PMID: 32130499 PMCID: PMC7293664 DOI: 10.1007/s00415-020-09748-w
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Fig. 1Schematic representation of the additional deleterious effects of postural blood pressure hypotension in cerebral small vessel disease associated dizziness in addition to cortico-subcortical (1), and cortico-cortical (2) disconnectivity. Localized oxidative stress processes damage the cerebral vasculature, leading to endothelial dysfunction and promoting neurodegenerative alterations in the brain tissue through reactive oxidative species (ROS). Microvascular endothelial dysfunction in turn disrupts cerebral autoregulation—which in healthy states maintains adequate and stable cerebral blood flow when blood pressure drops (3). This leads to intra-cerebral orthostatic hypotension and perfusion, manifest as postural light-headedness and imbalance.
From Kaski et al. [10] with permission
Bárány Society diagnostic criteria for persistent postural perceptual dizziness
| (A) One or more symptoms of dizziness, unsteadiness or non-spinning vertigo on most days for at least 3 months |
| Symptoms last for prolonged (hours-long) periods of time, but may wax and wane in severity |
| Symptoms need not be present continuously throughout the entire day |
| (B) Persistent symptoms occur without specific provocation, but are exacerbated by three factors: upright posture, active or passive motion without regard to direction or position, and exposure to moving visual stimuli or complex visual patterns |
| (C) The disorder is triggered by events that cause vertigo, unsteadiness, dizziness, or problems with balance, including acute, episodic or chronic vestibular syndromes, other neurological or medical illnesses, and psychological distress |
| When triggered by an acute or episodic precipitant, symptoms settle into the pattern of criterion A as the precipitant resolves, but may occur intermittently at first, and then consolidate into a persistent course |
| When triggered by a chronic precipitant, symptoms may develop slowly at first and worsen gradually |
| (D) Symptoms cause significant distress or functional impairment |
| (E) Symptoms are not better accounted for by another disease or disorder |
Summary of studies on preventive treatments for vestibular migraine defined based on the ICHD-3 criteria.
(from [20])
| Drug | Daily dose | Study design | Duration | Outcome | |
|---|---|---|---|---|---|
| Propranolol* | 40–160 mg | 33 patients, prospective, randomized, controlled | 4 months | Severity: DHI 55.8 ± 2.7 to 31.3 ± 3.7* VSS 7.3 ± 0.3 to 2.1 ± 0.4* Attacks per month: 12.6 ± 1.8 to 1.9 ± 0.7 | Salviz et al. [ |
| Venlafaxine | 37.5–150 mg | 31 patients, prospective, randomized, controlled | 4 months | Severity: DHI 50.9 ± 2.5 to 19.9 ± 2.9* VSS 7.1 ± 0.3 to 1.8 ± 0.5* Attacks per month: 12.2 ± 1.8 to 2.6 ± 1.1 * | Salviz et al. [ |
| Venlafaxine | 37.5 mg | 25 patients, prospective | 3 months | Severity: DHI 41.7 ± 16.9 to 31.3 ± 14.1* VSS 5.9 ± 1.7 to 3.8 ± 1.2* | Liu et al. [ |
| Flunarizine | 10 mg | 25 patients, prospective | 3 months | Severity: DHI 46.6 ± 15.1 to 39.8 ± 16.3* VSS 6.4 ± 1 .9 to 5.9 ± 1.6* | Liu et al. [ |
| Valproic acid | 1000 mg | 25 patients, prospective | 3 months | Severity: DHI 46.8 ± 13.5 to 38.7 ± 13.6* VSS 5.8 ± 1.8 to 5.3 ± 1.0 | Liu et al. [ |
| Cinnarizine | 75 mg | 24 patients, retrospective open-label | 3 months | Attacks per month: 3.8 ± 1.1 to 0.4 ± 0.6* | Taghdiri et al. [ |
DHI Dizziness handicap inventory, VSS Vertigo Severity score (Liu et al.)
*p < 0.05